Is CyberArk The Next Big Cybersecurity Stock?
CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…
Buy
78
EXEL Quote, Financials, Valuation and Earnings
Last price:
$36.37
Seasonality move
:
6.23%
Day range:
$36.62 - $37.23
52-week range:
$20.14 - $40.02
Dividend yield:
0%
P/E ratio:
20.92x
P/S ratio:
5.06x
P/B ratio:
4.62x
Volume:
2.1M
Avg. volume:
2.6M
1-year change:
61.1%
Market cap:
$10.4B
Revenue:
$2.2B
EPS (TTM):
$1.77
Analysts' Opinion
-
Consensus RatingExelixis has received a consensus rating of Hold. The company's average rating is a Hold based on 7 Buy ratings, 9 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $37.06, Exelixis has an estimated upside of 0.11% from its current price of $37.02.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $23.00 representing 100% downside risk from its current price of $37.02.
Fair Value
-
According to the consensus of 16 analysts, Exelixis has 0.11% upside to fair value with a price target of $37.06 per share.
EXEL vs. S&P 500
-
Over the past 5 trading days, Exelixis has underperformed the S&P 500 by -6.72% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Exelixis does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Exelixis has grown year-over-year revenues for 8 quarters straight. In the most recent quarter Exelixis reported revenues of $566.8M.
Earnings Growth
-
Exelixis has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Exelixis reported earnings per share of $0.48.
Enterprise value:
9.2B
EV / Invested capital:
4.12x
Price / LTM sales:
5.06x
EV / EBIT:
13.41x
EV / Revenue:
4.27x
PEG ratio (5yr expected):
0.12x
EV / Free cash flow:
14.59x
Price / Operating cash flow:
17.30x
Enterprise value / EBITDA:
12.87x
Gross Profit (TTM):
$2.1B
Return On Assets:
18.07%
Net Income Margin (TTM):
24.04%
Return On Equity:
23.63%
Return On Invested Capital:
23.63%
Operating Margin:
28.84%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $1.6B | $1.8B | $2.2B | $479.7M | $566.8M | |
| Gross Profit | $1.6B | $1.8B | $2.1B | $457.9M | $546.8M | |
| Operating Income | $201.5M | $170.9M | $689.9M | $81.8M | $163.5M | |
| EBITDA | $222.4M | $196.6M | $718.8M | $88.3M | $171.1M | |
| Diluted EPS | $0.57 | $0.64 | $1.77 | $0.27 | $0.48 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.4B | $1.8B | $1.6B | $1.3B | $1.5B | |
| Total Assets | $2.1B | $2.6B | $3.1B | $2.9B | $2.9B | |
| Current Liabilities | $204.7M | $337.6M | $324.4M | $394.3M | $403.8M | |
| Total Liabilities | $258.2M | $405.6M | $583.1M | $678.4M | $703.5M | |
| Total Equity | $1.9B | $2.2B | $2.5B | $2.3B | $2.2B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $362.6M | $333.3M | $700M | $10.6M | $240.3M | |
| Cash From Investing | -$524.4M | -$27M | -$116.8M | $61.7M | -$93.2M | |
| Cash From Financing | $586K | -$546.1M | -$628.8M | -$206.2M | -$188M | |
| Free Cash Flow | $224.2M | $170.4M | $633.8M | -$2.6M | $226.3M | |
EXEL
Sector
Market Cap
$10.4B
$37.4M
Price % of 52-Week High
92.5%
45.61%
Dividend Yield
0%
0%
Shareholder Yield
6.95%
-0.75%
1-Year Price Total Return
61.1%
-38.36%
Beta (5-Year)
0.571
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$37.51
200-day SMA
Buy
Level
$29.36
Bollinger Bands (100)
Buy
Level
32.07 - 36.91
Chaikin Money Flow
Buy
Level
57.9M
20-day SMA
Buy
Level
$36.92
Relative Strength Index (RSI14)
Buy
Level
52.86
ADX Line
Buy
Level
27.75
Williams %R
Buy
Level
-83.1025
50-day SMA
Buy
Level
$35.16
MACD (12, 26)
Buy
Level
0.70
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
826.3M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (9.8959)
Buy
CA Score
(Annual)
Level (2.0984)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-4.4265)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Stock Forecast FAQ
In the current month, EXEL has received 7 Buy ratings 9 Hold ratings, and 0 Sell ratings. The EXEL average analyst price target in the past 3 months is $37.06.
-
Where Will Exelixis Stock Be In 1 Year?
According to analysts, the consensus estimate is that Exelixis share price will rise to $37.06 per share over the next 12 months.
-
What Do Analysts Say About Exelixis?
Analysts are divided on their view about Exelixis share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Exelixis is a Sell and believe this share price will drop from its current level to $23.00.
-
What Is Exelixis's Price Target?
The price target for Exelixis over the next 1-year time period is forecast to be $37.06 according to 16 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 9 analysts rate the stock a Hold.
-
Is EXEL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Exelixis is a Hold. 9 of 16 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of EXEL?
You can purchase shares of Exelixis via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Exelixis shares.
-
What Is The Exelixis Share Price Today?
Exelixis was last trading at $36.37 per share. This represents the most recent stock quote for Exelixis. Yesterday, Exelixis closed at $37.02 per share.
-
How To Buy Exelixis Stock Online?
In order to purchase Exelixis stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is the Market Going to Go Lower?
The last month has been extremely difficult for the stock…
2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
52
RGC alert for Mar 18
Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.
Buy
63
EXOD alert for Mar 18
Exodus Movement [EXOD] is down 3.96% over the past day.
Sell
45
MNPR alert for Mar 18
Monopar Therapeutics [MNPR] is up 0.93% over the past day.
